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Abstract
Background
Oral magnesium supplementation is commonly used to support a low magnesium diet. This
investigation set out to determine whether magnesium in a cream could be absorbed trans-
dermally in humans to improve magnesium status.
Methods and findings
In this single blind, parallel designed pilot study, n = 25 participants (aged 34.3+/-14.8y,
height 171.5+/-11cm, weight 75.9 +/-14 Kg) were randomly assigned to either a 56mg/day
magnesium cream or placebo cream group for two weeks. Magnesium serum and 24hour
urinary excretion were measured at baseline and at 14 days intervention. Food diaries were
recorded for 8 days during this period. Mg test and placebo groups’ serum and urinary Mg
did not differ at baseline. After the Mg2+ cream intervention there was a clinically relevant
increase in serum magnesium (0.82 to 0.89 mmol/l,p = 0.29) that was not seen in the pla-
cebo group (0.77 to 0.79 mmol/L), but was only statistically significant (p = 0.02)) in a sub-
group of non-athletes. Magnesium urinary excretion increased from baseline slightly in the
Mg2+ group but with no statistical significance (p = 0.48). The Mg2+ group showed an 8.54%
increase in serum Mg2+ and a 9.1% increase in urinary Mg2+ while these figures for the pla-
cebo group were smaller, i.e. +2.6% for serum Mg2+ and -32% for urinary Mg2+. In the pla-
cebo group, both serum and urine concentrations showed no statistically significant change
after the application of the placebo cream.
Conclusion
No previous studies have looked at transdermal absorbency of Mg2+ in human subjects. In
this pilot study, transdermal delivery of 56 mg Mg/day (a low dose compared with commer-
cial transdermal Mg2+ products available) showed a larger percentage rise in both serum
and urinary markers from pre to post intervention compared with subjects using the placebo
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Introduction
Mineral elements, such as magnesium (Mg2+), are required by the human body in modest
amounts for the maintenance of health and the development of optimal functioning[1]). Mg2+
is an important mineral element and it is the fourth most abundant cation in living organisms,
with Mg2+ being a cofactor to over 325 enzymatic reactions within the body [2]. Around 99%
of total body Mg2+ is located in the bone, muscles and non-muscular soft tissue [3]. Mg2+ sup-
plementation has been shown to significantly improve blood pressure [4–6] as well as modify-
ing vascular tone by regulating endothelium and smooth muscle cell function [4].
To maintain an adequate Mg2+ status humans must consume Mg2+ at regular intervals [7].
The daily recommendation for Mg2+ is controversial, as the literature is conflicting and varies
between countries, although values of 300 mg/day are usually reported for healthy adults
with adjustment for age, sex and nutritional status [7].
Oral magnesium supplementation has been shown to affect various parameters, such as
blood pressure [5,8], immune function [9], cardiovascular system [10] and metabolic syn-
drome [11]. A recent meta-analysis by Zhang et al (2016) in the Journal of Nutrition [12]
found that in a healthy population group there was a dose dependent increase in both serum
Mg concentration and urinary Mg excretion with supplemental oral magnesium intake rang-
ing from 250–500mg/day. Kass, Weekes and Carpenter (2012) identified that a supplement of
>370 mg/day of Mg+ shows greater efficacy than a lower dose in improving blood pressure
and that magnesium supplementation gives a dose dependent response with regards to blood
pressure [5].
An alternative method of perhaps attaining recommended magnesium intakes might be
through topical application. Current formulations include magnesium oils and trans-dermal
creams, from which the magnesium may be absorbed across the skin and into the systemic cir-
culation. However, in contrast to gastrointestinal epithelium, a primary function of the skin is
to act as a barrier, which restricts the absorption of exogenous chemicals into the body. The
barrier function of the skin is thought to lie predominately in the outermost layer of the epi-
dermis, the stratum corneum. The stratum corneum is thought to largely present a hydropho-
bic barrier to the absorption of transdermal creams. The dermis, immediately below the
epidermis, contains the blood vessels that are able to transport substances that have permeated
the skin into the systemic circulation.
Although less studied than organic molecules, metal ions are known to be able to cross the
skin, with the literature having focussed on metals that are known to cause irritant/toxic effects
[13]. The lower resistance to permeation of the skin appendages, skin structures that serve a
particular function including sensation, lubrication and heat loss, and the ionised nature of
metals means that their permeation across these skin appendages is considered to be the most
likely route of absorption [13,14]. However, the low surface area available for this in human
skin means that metal ion absorption across skin is expected to be relatively low. Therefore, it
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has been questioned that a transdermal route of administration might provide sufficient Mg2+
absorption to help meet systemic Mg2+ requirements. This investigation aims to determine if
transdermal absorption of Mg2+ from a topical cream occurs “in vivo” in humans.
To date, no study has investigated the absorbency of transdermal magnesium cream in
human subjects. Commercially available Mg2+ topical applications range from 75mg to 400mg
depending on the dosage recommended by manufacturers. This ranges from 5–30 sprays of
magnesium oil or 2–4 teaspoons of magnesium cream, which can be applied in one application
or throughout the day. Disappointingly, many commercial topical creams and oils do not state
the concentration of magnesium in the product.
This study was designed as a first time, pilot study to ascertain whether such a topical Mg2+
preparation might affect urinary or serum Mg2+. Since less than 1% of magnesium is contained
in the blood, assessment by serum status may be problematic [3]. It is often considered that 24-hr
urine excretion of Mg2+ may be a better indicator of intestinal absorption than serum concentra-
tion; however, urinary Mg2+ excretion is also highly variable and it is questionable whether it can
be used reliably to assess an individual’s Mg2+ status [15]. However, serum Mg2+ can reflect a lon-
ger term dietary Mg2+ status over weeks or months whilst urinary Mg2+ can be a better marker of
one’s recent dietary intake [16]. These studies using serum and urinary Mg2+ markers in dietary
Mg2+ research could not be assumed to be helpful in the design of this study. Djurhuus et al,[17],
however, reported that although it is unlikely that a single determination of serum Mg2+ can be
used in assessing whole-body Mg2+ status in an individual, serial determinations of serum Mg2+
might prove useful as an indicator of changes in whole body Mg2+ status. These authors also
found that 24-hr urinary Mg2+ excretion is unlikely to be a reliable measure of whole body Mg2+
status and is not a good marker to measure changes in whole body Mg2+ status. Nonetheless, we
decided to use 24-hr urinary Mg2+ as well as serum Mg2+ in this pilot study.
Therefore, the purpose of this pilot study was to investigate whether a 56 mg/day dose of
magnesium in a cream, applied transdermally to humans, would affect either serum magne-
sium levels or urinary excretion over a two-week period and to measure effect, if any, and vari-
ance to inform a properly powered future study, if warranted.
Methods
Recruitment
Subject recruitment started April 2014 and data collection and follow-up was completed by
February 2015. The study was not registered on a CT Database at the time of subject recruit-
ment as trial registration in these kinds of studies is not commonly practiced. The trial was
subsequently registered in order to comply with publication requirements according to the
WHO guidelines. The authors confirm that all ongoing and related trials for this intervention
are registered.
Participants
Twenty-five healthy adults (female = 13 male = 12) aged 34.3+/-14.8y, height 171.5+/-11cm,
weight 75.9 +/-14 Kg, were recruited from the staff and student population of the University of
Hertfordshire and word of mouth to local residents and randomly assigned into either a magne-
sium cream or placebo cream group by random allocation. Randomisation was determined by
allocation to a group selected from a box with equal amounts of paper stating either placebo or
magnesium and selected at time of recruitment. The trial was single blind with only the lead
investigator being aware of the content of the cream. One participant dropped out of study
before completion. Participants were excluded if they were taking magnesium supplementation
in any form within a month of recruitment onto the trial, were under the age of 18y or above
Transdermal magnesium cream absorption
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the age of 60y.There were no height or weight restrictions, Written informed consent was com-
pleted and ethical approval was granted by the University of Hertfordshire Health and Human
Science Ethics Committee on 14th April 2014. Blood collection and blood and urine analysis
was undertaken at the University of Hertfordshire Human Physiology Laboratory.
Dietary magnesium intake was below the RNI in one of the placebo participants and three
of the magnesium participants. This was not considered a bar to inclusion into the study as
any change in serum or urinary Mg2+ from the cream could still be shown. High levels of
physical exercise have been shown to deplete human Mg2+ status ([18]. Four participants were
considered “athletes” as they engaged in at least 2hrs of physical exercise at least 5 days per
week during the study, three who were assigned to the Mg2+ intervention group and one
assigned to receive placebo. All other 20 participants who completed the study were considered
“non-athletes”, i.e. engaging in less than 2 hrs physical exercise per day for no more than 3
days per week during the study. Participants were instructed not to exercise 24h before blood
draws, but “athletes” may have disregarded this instruction, so results were statistically ana-
lysed in two ways: 1. “all subjects”, including both athletes and non-athletes (n = 24 who com-
pleted the study) and 2. “non-athletes” (n = 20) which excluded the 4 athletes. Baseline serum
and urine Mg2+ concentrations as well as dietary Mg2+ recorded in the randomised interven-
tion and placebo groups did not differ significantly from each other (P<0.05) (Tables 1 & 2) in
either the “all subjects” or “non-athletes” groupings.
Baseline measurements
Baseline data consisted of a 24 hour urinary collection to assess baseline magnesium excretion
and venous bloods to assess serum magnesium levels. (Tables 1 and 2). Urine was collected
from the second urinary passing of the day until and including the first urinary passing of the
next day. Blood collection could take place at any time of the day to suit the participants but
each participant had to return at that same timeslot for the second blood collection. No food
was allowed for the 3 hours before blood collection although water was allowed.
Dietary analysis
Each participant recorded a 4-day food diary (3 midweek days and 1 weekend day) prior to the
intervention plus a second 4-day food diary at the end of the 12–14 day period, giving a total
of 8 days dietary analysis over the period of the intervention for each participant. This was ana-
lysed for Mg2+ intake using Diet Plan 6 software (Forestfield Software Ltd., West Sussex, UK).
(Tables 1 and 2).
Intervention
After baseline measurements were taken, participants were randomly assigned to either the
Mg2+ Cream or a placebo control cream and were instructed to apply 2 x 5ml spoonfuls of
cream per day for two weeks. The resulting daily Mg2+ dose received by subjects in the Mg2+
Table 1. Demographic and baseline serum, urine and dietary magnesium (mean +/- s.d. [range]) for all
subjects, athletes plus non-athletes.
Magnesium group N = 14 Placebo group N = 10
Age (years) 34.8±15.3 36.6±14.6
Height (cm) 171.2±8.9 173.8±12.4
Weight Kg) 77.5±15.9 75.6±11.5
Serum (mmo/l) 0.82±0.18 [0.62–1.24] 0.773±0.16 [0.56–1.16]
Urine (mmol/24h) 4.07±1.62 [1.30–7.00] 4.6±2.1 [2.7–9.0]
Dietary 9Mg) 294.9±93.8 [176–496] 329.1±91.9 [196–482]
https://doi.org/10.1371/journal.pone.0174817.t001
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group consisted of 56mg of Mg2+. This was manufactured, in the course of research and devel-
opment, for the Center for Magnesium Education & Research by Urist Cosmetics of Vancou-
ver, B.C. Canada. For full ingredients see S1 Text Ingredients list.
The placebo was a commercially available aqueous cream containing no magnesium (by anal-
ysis) and creams were packaged identically. Instructions to participants suggested that Mg2+ or
placebo cream be applied to the stomach and torso in the first instance and then spread down to
the legs. Time of day was not important, but no showering or washing could take place for a
minimum of 3 hours after application. After 12–14 days, final urine and blood samples were col-
lected. The cream was applied up to and including the day of the final urine and blood collection.
Participants were instructed to stop use of the cream if there was any adverse reaction, of which
there were none. At the end of the trial compliance was ensured from verbal communication as
well of collection of the trans-dermal cream container to ensure full usage.
Sample collection
Serum blood samples were collected by venepuncture from the median cubital, basillic or
cephalic vein. Serum separator vacutainers were inverted 10 times before being left to rest for
30 minutes. Subsequently, samples were centrifuged at 3000 rpm for 10 minutes. Serum was
checked to be free from haemolysis and was immediately pipetted and frozen at -80˚C for sub-
sequent analysis
Urine was collected into 3 litre collection vessels over 24 hours. Urine was then decanted into
a measuring vessel and volume of urine was recorded. The measuring vessel was then placed on
a magnetic stirrer at 100rpm. To re-suspend the Mg2+, the pH was lowered to 3–3.25 by adding
5 M hydrochloric acid. Duplicate 1mL aliquots were frozen at -80˚C for batch analysis.
Analyses
Urine and serum samples were analysed by colorimetric assay for magnesium (RX MONZA,
Randox Laboratories Limited, County Antrim, United Kingdom). The machine was calibrated
according to the manufacturer’s instructions and results were calculated from the standard
concentration curve generated using the manufacturer’s calibration standard. Low urinary
and serum Mg2+ were determined to be below 3.0mmol/24h and 0.65mmol/l respectively [19].
All urine and serum samples were frozen and stored at -80˚C for between 4–12 weeks.
Data analysis
Serum and urinary Mg2+ data for both pre and post intervention were analysed for skewness
and normality prior to statistical analysis. All data passed the normality test so a standard two
tailed, paired t-test was used to compare baseline to post-intervention values (serum and uri-
nary Mg) for within group analysis.
Table 2. Demographic and baseline serum, urine and dietary magnesium (mean +/- s.d. [range]) for
non-athletes only.
Magnesium group N = 11 Placebo group N = 9
Age (years) 34.6±13.7 38.5±14.6
Height (cm) 169.7±9.4 175.0±12.5
Weight (Kg) 75.6±17.1 75.8±12.1
Serum (mmol/l) 0.75±0.13 [0.62–1.07] 0.73±0.09 [0.56–0.85]
Urine (mnol/24h) 4.08±1.34 [2.02–6.11] 4.80±2.1 [2.9–9.0]
Dietary (mg) 285.8±82.2 [177–469] 331.0±97.3 [196–482]
https://doi.org/10.1371/journal.pone.0174817.t002
Transdermal magnesium cream absorption
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Statistical analysis was conducted using SPSS V22 (IBM, New York, USA), with P value
value of0.05 accepted as statistically significant.
Results
Of the 29 subjects recruited, 1 was excluded for not meeting the criteria and 3 declined to par-
ticipate after baseline data was collected. Fourteen participants were allocated to the magne-
sium intervention group and completed the trial. Eleven were allocated to the placebo
intervention from which one dropped out due to adverse reaction to the venepuncture at the
Fig 1. CONSORT flow diagram, showing inclusion and exclusion of participants in the study.
https://doi.org/10.1371/journal.pone.0174817.g001
Transdermal magnesium cream absorption
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baseline blood collection before cream had been administered. Fig 1 depicts the inclusion and
exclusion of the participants in the study.
Urinary and serum response to trans-dermal magnesium application
Mean serum and 24-hour urinary Mg2+ concentrations were obtained for all participants
before and after a 2-week application period of the magnesium or placebo trans-dermal
cream. Baseline (Tables 1 & 2) serum Mg2+ values were below normal reference values
(0.65mmol/l) in one magnesium intervention participant and one placebo participant (both
non-athletes), whilst the baseline 24-hr urinary Mg2+ excretion was below normal (3.0mmol/
24h) in two placebo participants (one non-athlete, one athlete) and three magnesium partici-
pants (two non-athletes, one athlete); these were different participants for both the serum and
urine. Of the five participants with low urinary excretion, three had below the RNI for dietary
Mg2+ intake however this was not the case for the low serum Mg2+ subjects.
All participants, Table 3
There was no statistically significant effect of Mg2+ cream on either serum or urinary Mg2+ sta-
tus. However, after the Mg2+ cream intervention there was a clinically relevant increase [11, 19]
in serum magnesium (0.82 to 0.89 mmol/l) that was not seen in the placebo group (0.77 to 0.79
mmol/L), but this was not statistically significant (p = 0.29). Similarly, there was a slight increase
in magnesium urinary excretion in the Mg2+ group but again no statistical significance
(p = 0.48). A percentage increase of 8.54% for serum Mg2+ and 9.1% in urinary Mg2+ was seen
in the Mg2+ group while for the placebo group these figures were smaller, i.e. +2.6% for serum
Mg2+ and -32% for urinary Mg2+. In the placebo group both serum and urine concentrations
showed no statistically significant change after the application of the placebo cream.
Non-athletes, Table 4
For non-athlete participants (n = 11 in Mg group plus n = 9 in placebo group), there was a sta-
tistically significant rise (P = 0.02) in serum Mg2+ in the intervention group which was not
seen in the placebo group. Serum Mg2+ in the intervention showed a % change of +22.7%
while that in the placebo group showed a +4.11% rise. Urinary Mg2+ did not show any signifi-
cant change in either Mg2+ or placebo group although a large non-significant negative change
could be seen in the placebo group (-32.50%) when compared with the 11.3% increase in the
intervention group.
Discussion
Transdermal Mg2+ effect on serum Mg2+
Previous study of humans have shown that serial determinations of serum Mg2+ can prove
useful as an indicator of changes in whole body Mg2+ status[17]. From this study, 56 mg/day
Table 3. Influence of Trans-dermal Magnesium vs placebo cream application on Serum and Urinary Magnesium Concentrations (mean +/- S.D.)
for all subjects, athletes plus non-athletes.
Serum Concentrations, (mmol/L) Urinary Excretion (mmol/24h)
Intervention Magnesium (n = 14) Placebo (n = 10) Magnesium (n = 14) Placebo (n = 10)
Pre 0.82±0.18 0.77±0.16 4.07±1.62 4.6±2.1
Post 0.89±0.18 0.79±0.18 4.44±1.56 3.12±1.27
%Change +8.54% +2.6% +9.1% -32%
https://doi.org/10.1371/journal.pone.0174817.t003
Transdermal magnesium cream absorption
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Mg2+ applied as transdermal cream for 12–14 days had no statistically significant effect on
serum concentration in this small (n = 25) human study when both athletes and non-athletes
were included in the statistical analyses. However, a trend towards a rise in serum Mg2+ in the
Mg2+ group could be seen with an increase of 0.07mmol/l, a clinically relevant rise in a mea-
surement that is greater than many previous studies and a rise that would take months to show
change with oral Mg2+ therapy [11, 19]. Zhang et al., [11] reported that in 41 trials, 941 partici-
pants receiving a mean oral Mg supplement of 365 mg/day for a median of 12 weeks showed a
mean rise of 0.05 mmol/L circulating Mg (0.78 to 0.83 mmol/L). A meta-analysis of 27 trials by
Zhang et al [8] investigating oral Mg2+ supplementation, showed a significant (p<0.001) rise
in serum Mg with 200 mg/day oral Mg supplement or one month supplement duration but
that higher doses ( 300 mg/day) or durations of supplementation (2 months) were required
to achieve a mean rise of 0.05 mmol/l in serum Mg2+. Additionally, studies included in the
Zhang et al [8] meta-analysis show a baseline mean C.V. for the 27 serum Mg2+ studies of 9.3%
for Mg groups and 10.8% for placebo groups, i.e. as little as half of the variance for baseline
serum Mg2+ measurements in this study (C.V. = 21.9% and 17.3% for Mg2+ groups, all subjects
and non-athletes respectively; C.V. = 20.7% and 12.3% for placebo groups, all subjects and
non-athletes respectively). This pilot study of all subjects, both athletes and non-athletes,
shows that transdermal Mg2+ may possibly influence serum Mg2+ in a relatively short time
frame (12–14 days), but a higher concentration of Mg2+ cream, a larger number of subjects
given the serum Mg2+ variance, and perhaps a longer study is required to make any real
conclusion.
Although participants were told to refrain from exercise for 24 hours before blood and uri-
nary collection, 4 participants were undertaking regular high intensity training, the effects of
which may affect Mg2+ parameters that can last longer than 24 hours [18]. When the data from
these four subjects were removed from the statistical analysis a significant effect of the Mg2+
cream on serum Mg2+ concentrations could be seen.(p = 0.02). Additionally, the %rise in
serum Mg2+ in the non-athletes (+22.7%) was much larger than that shown in all subjects, i.e.
both athletes and non-athletes (+8.54%). This is too small a sample size to reach a firm conclu-
sion but this increase in percentage change in the non-athlete intervention group may be due
to an additional uptake of Mg2+.from the cream which may have been utilised during exercise
or for replenishment of Mg2+ stores rather than being transferred to serum in the athletic par-
ticipants. This is an area of interest for further study.
Further, this analysis of the serum Mg data for the non-athletes in the intervention group
showed a mean increase from 0.75 to 0.92 mmol/l which may have clinical relevance in partic-
ular with relation to cardiovascular disease. In a meta-analysis by Del Gobbo et al (2013)[20],
it was found that a rise of 0.2 mmol/L circulating Mg was associated with a 30% lower risk of
cardiovascular disease and fatal ischemic heart disease. In addition, Lutsey et al.(2014) [21]
found that after 20+ yrs follow up serum Mg showed a linear inverse association with the risk
Table 4. Influence of Trans-dermal Magnesium vs placebo cream application on Serum and Urinary Magnesium Concentrations (mean +/- S.D.)
for non-athlete subjects.
Serum Concentrations, (mmol/L) Urinary Excretion (mmol/24h)
Intervention Magnesium (n = 11) Placebo (n = 9) Magnesium (n = 11) Placebo (n = 9)
Pre 0.75±0.13 0.73±0.09 4.08±1.34 4.80±2.10
Post 0.92±0.18* 0.76±0.17 4.54±1.75 3.24±1.28
%Change +22.7% +4.11% +11.27% -32.50%
* P<0.02 compared with “pre-serum Mg2+ value
https://doi.org/10.1371/journal.pone.0174817.t004
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of incident heart failure. Relative to those in the highest category of serum Mg, those in the
lowest category were at 2.58 times greater risk of incident heart failure after demographic
adjustments. In these quintiles, the lowest serum Mg quintile was 0.7 mmol/L, the second was
0.75, the third was 0.8, the 4th was 0.85 and the highest was 0.9 mmol/L, i.e. each quintile was
0.05 mmol/l higher than the next lowest quintile (these results were converted from mEq/L by
dividing by 2 to attain mmol/L). Our results show a mean rise of 0.05 mmol/L serum Mg2+
with daily application of transdermal Mg2+ for only two weeks, and when considering this Lut-
sey[21] study and the Del Gobbo[20] results, our finding suggests a possibly significant favour-
able impact of transdermal Mg on risk of heart failure that needs full study.
Transdermal Mg effect on urinary Mg2+
Previous study of humans has suggested that 24-hr urinary Mg2+ excretion cannot be used as a
measure of changes in whole body Mg2+ status [17].
Upon analysis for all subjects, as well as for only non-athletes, use of the transdermal Mg2+
cream showed no significant rise in urinary Mg2+, a measurement that reflects short term
intestinal absorption of Mg2+. However, subjects in the Mg2+ group showed slight rises in uri-
nary Mg2+ (+9 to 11%) while those in placebo group showed a substantial decrease in urinary
Mg2+ (-32%). Possibly the decreased urinary Mg2+ excretion in the placebo cream group repre-
sents more active physiological Mg2+ retention processes that are not apparent in the Mg
cream group ([15,16]. It has been suggested that 24-hour urine excretion of Mg2+ may be a bet-
ter indicator of tissue status than the serum Mg2+ concentration, but it is highly variable and it
is questionable whether it can be used to reliably assess a given individual’s Mg2+ status.
The trans-dermal cream contained 56 mg of Mg2+ administered daily. This is at the lower
end of creams sold commercially. The recommended dose of the few commercially available
creams range between 70mg/d to 400mg/d per day, therefore results of this study may repre-
sent an “underdose” of transdermal Mg2+.
Conclusion
No previous studies have looked at effects of transdermal Mg2+ in human subjects. In this two-
week pilot study, transdermal delivery of 56 mg Mg/day (a low dose compared with commer-
cial transdermal Mg2+ products available) showed a larger percentage change in both serum
and urinary markers from pre to post intervention compared with subjects using the placebo
cream. In addition, the rise in mean serum Mg2+ seen in the Mg2+ group was clinically relevant
although only statistically significant (p<0.05) when non-athletes were analysed separately.
Given the high variance in serum Mg2+ of these subjects, we suggest that future research
focus on a larger number of human subjects given higher concentrations of Mg2+ cream appli-
cation administered for longer durations to investigate whether transdermal application may
show a significant contribution to improvement in magnesium status. It would also be of
interest to look at the effect of transdermal Mg2+ supplementation on athletes as compared to
a sedentary population group.
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